![]() |
Joele Frank is handling Forma Therapeutics as the Watertown, MA-based biopharmaceutical company focused on sickle cell disease and other blood disorders is acquired by Novo Nordisk for $1.1B cash.
The Danish company has developed Etavopivat, which is currently being evaluated in global trials to treat sickle cell disease.
“Novo Nordisk has worked for more than 40 years to develop and deliver transformative medicines to patients around the world with rare and devastating diseases,” said Ludovic Helfgott, EVP and head of rare disease unit.
The addition of Forma’s ‘differentiated approach’ to address unmet needs for patients is a step forward in enhancing our sickle cell disease pipeline.” added Helftogg.
Joele Frank, Wilkinson Brimmer Katcher’s Jamie Moser and Greg Klassen represent Forma Therapeutics.


Wendy’s has turned to Collected Strategies as it rejects what it calls an inadequate, unsolicited and non-binding takeover bid from a group led by Nelson Peltz’s Trian Partners.
Collected Strategies and AdvisRy Partners will handle Kaz Resources when it goes public in a $2B deal during the first half of next year.
FGS Global handles Marvell Technology as the semiconductor giant agrees to acquire Lumentum, a Joele Frank client, in all all-stock transaction worth $115B.
Ross Lovern, who advised clients on such matters as internal and external crises, M&A, litigation, restructurings and shareholder activism as a partner at Kekst CNC, has joined Prosek Partners as a managing director on its special situations team in New York.
Joele Frank handles Vail Resorts as it works to win a proxy fight against Hong Kong activist fund Oasis Management, owner of 9.6 percent of the company.



